Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate

Journal of Surgical Research

Volumn 86, Issue 1, 1999, Pages 24-28

  Schwartz, Charles F ^b   Kilgore, Kenneth S ^a   Homeister, Jonathon W ^a   Levy, Benjamin A ^a   Lucchesi, Benedict R ^a   Bolling, Steven F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Complement system; Glycosaminoglycans; Heart transplantation

Indexed keywords

CYCLOSPORIN; HEPARIN; PENTOSAN POLYSULFATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032876936     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5704     Document Type: Article

References (25)

1. Maffrand J. P., Hergert J. M., Bernat A., Defreyn G., Delebassee D., Savi P., Pinot J. J., Sampol J. Experimental and clinical pharmacology of pentosan polysulfate. Semin. Thromb. Hemostasis. 17:1991;186.
2. Odlind B., Dencker L., Tengblad A. Preferential localization of 3H-pentosanpolysulphate to the urinary tract in rats. Pharmacol. Toxicol. 61:1987;162.
3. Parsons C. L., Mulholland S. G. Successful therapy of interstitial cystitis with pentosanpolysulfate. J. Urol. 138:1987;513.
4. Parsons C. L., Benson G., Childs S. J., Hanno P., Sant G. R., Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J. Urol. 150:1993;845.
5. Smith M. M., Ghosh P., Numata Y., Bansal M. K. The effects of orally administered calcium pentosan polysulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex. Arthr. Rheum. 37:1994;125.
6. Kilgore K. S., Naylor K. B., Tanhehco E. J., Park J. L., Lucchesi B. R. The semi-synthetic polysaccharide pentosan polysulfate prevents complement-mediated injury in the rabbit perfused heart. J. Pharmacol. Exp. Ther. 285:1998;987.
7. Schowengerdt K. O., Zhu J. Y., Stepkowski S. M., Tu Y., Entman M. L., Ballantyne C. M. Cardiac allograft survival in mice deficient in intracellular adhesion molecule-1. Circulation. 92:1995;82.
8. Fey T. A., Krause R. A., Hsieh G. C., Andrews J. M., Bretheim P. T., Morgan S. J., Luly J. R., Mollison K. W. Improved methods for transplanting split-heart neonatal cardiac grafts into the ear pinna of mice and rats. J. Pharmacol. Toxicol. Methods. 39:1998;9.
9. Sykes M. Immunobiology of transplantation. FASEB J. 10:1996;721.
10. Lawson J. H., Platt J. L. Molecular barriers to xenotransplantation. Transplantation. 62:1996;303.
11. Leventhal J. R., Dalmasso A. P., Cromwell J. W., Manivel C. J., Bolman R. M. III, Matas A. J. Complement depletion prolongs discordant cardiac xenograft survival in rodents and non-human primates. Transplant. Proc. 25:1993;398.
12. Brauer R. B., Baldwin W. M. III, Daha M. R., Pruitt S. K., Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J. Immunol. 151:1993;7240.
13. Foreman K. E., Vaporciyan A. A., Bonish B. K., Jones M. L., Johnson K. J., Glovsky M. M., Eddy S. M., Ward P. A. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94:1994;1147.
14. Homeister J. W., Satoh P. S., Kilgore K. S., Lucchesi B. R. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. J. Immunol. 150:1993;1055.
15. Engelberg H. Update on the relationship of heparin to atherosclerosis and its thrombotic complications. Semin. Thromb. Hemostasis. 14:1988;88.
16. Hiebert L. M., McDuffie N. M. The intracellular uptake and protracted release of exogenous heparins by cultured endothelial cells. Artery. 16:1989;208.
17. Hiebert L. M., McDuffie N. M. The internalization and release of heparins by cultured endothelial cells: The process is cell source, heparin source, time and concentration dependent. Artery. 17:1990;107.
18. Hiebert L. M., Wice S. M., McDuffie N. M., Jaques L. B. The heparin target organ - The endothelium. Studies in a rat model. Q. J. Med. 86:1993;341.
19. Maillet F., Petitou M., Choay J., Kazatchkine M. D. Structure-function relationships in the inhibitory effect of heparin on complement activation: Independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol. Immunol. 25:1988;917.
20. Meri S., Pangburn M. K. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem. Biophys. Res. Commun. 198:1994;52.
21. Boackle R. J., Caughman G. B., Vesely J., Medgyesi G., Fudenberg H. H. Potentiation of factor H by heparin: A rate-limiting mechanism for inhibition of the alternative complement pathway. Mol. Immunol. 20:1983;1157.
22. Koistinen V. Effects of sulphated polyanions on functions of complement factor H. Mol. Immunol. 30:1993;113.
23. Ghosh P., Hutadilok N. Interactions of pentosan polysulfate with cartilage matrix proteins and synovial fibroblasts derived from patients with osteoarthritis. Osteoarthr. Cartilage. 4:1996;43.
24. Czarnowska E., Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Basic Res. Cardiol. 90:1996;357.
25. Ryan U. S. The endothelial surface and responses to injury. Fed. Proc. 45:1986;101.